266 related articles for article (PubMed ID: 19667303)
1. Thiazolidinediones and fractures in men and women.
Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
[TBL] [Abstract][Full Text] [Related]
2. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
3. Distal upper and lower limb fractures associated with thiazolidinedione use.
Jones SG; Momin SR; Good MW; Shea TK; Patric K
Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
[TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
[TBL] [Abstract][Full Text] [Related]
5. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
6. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
7. Use of thiazolidinediones and fracture risk.
Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy for diabetes is associated with increased use of lower endoscopy.
Lewis JD; Capra AM; Achacoso NS; Ferrara A; Levin TR; Quesenberry CP; Habel LA
Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1195-202. PubMed ID: 17603822
[TBL] [Abstract][Full Text] [Related]
9. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
10. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
11. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
[TBL] [Abstract][Full Text] [Related]
14. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes.
Peters Harmel AL; Kendall DM; Buse JB; Boyle PJ; Marchetti A; Lau H
Curr Med Res Opin; 2004; 20(2):215-23. PubMed ID: 15006017
[TBL] [Abstract][Full Text] [Related]
15. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
[TBL] [Abstract][Full Text] [Related]
16. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes.
Gerrits CM; Bhattacharya M; Manthena S; Baran R; Perez A; Kupfer S
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1065-71. PubMed ID: 17674425
[TBL] [Abstract][Full Text] [Related]
17. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
[TBL] [Abstract][Full Text] [Related]
18. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
Pinelli NR; Cha R; Brown MB; Jaber LA
Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
[TBL] [Abstract][Full Text] [Related]
19. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
20. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
Idris I; Warren G; Donnelly R
Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]